Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMAZON.COM, INC.

(AMZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amazon com : FDA notifies Amazon over sale of certain harmful sexual enhancement products

07/29/2021 | 11:56am EDT

July 29 (Reuters) - The U.S Food and Drug Administration (FDA) notified Amazon.com Inc over the sale of sexual enhancement and weight-loss products that had potentially harmful drug ingredients, in a letter addressed to the company's new boss Andy Jassy.

Amazon said it has removed the products in question, and will continue to work with the agency.

The FDA had already warned consumers in December https://www.fda.gov/news-events/press-announcements/fda-warns-consumers-avoid-certain-male-enhancement-and-weight-loss-products-sold-through-amazon-ebay to avoid male enhancement and weight-loss products sold through Amazon, eBay and other retailers, citing hidden, dangerous drug ingredients.

In a letter https://www.fda.gov/media/151096/download dated July 26, the FDA said it tested dozens of products it bought from December 2019 to February 2020 and found they contained one or more of the drug ingredients sildenafil, tadalafil and vardenafil.

None of these ingredients were named in the products' labeling, the health regulator said.

Sildenafil, tadalafil and vardenafil are active ingredients in FDA-approved prescription drugs Viagra, Cialis and Levitra, which are used to treat erectile dysfunction.

Those ingredients could interact with some prescription drugs and may lower blood pressure to dangerous levels, the FDA said.

"We continue to find potentially dangerous products available for purchase and urge stores, websites and online marketplaces, including Amazon, to do more to protect consumers by not selling or facilitating the sale of potentially dangerous and illegal FDA-regulated products," the health regulator said on Twitter on Thursday.

In one instance, the FDA said it had purchased a product from the Amazon website which the company had previously said it had restricted, adding it was concerned the e-commerce website's filters were inadequate.

The FDA has asked Amazon to submit a written response within 15 working days on steps it has taken to address such violations.

(Reporting by Nivedita Balu, Manas Mishra, and Tiyashi Datta in Bengaluru; Editing by Krishna Chandra Eluri)


© Reuters 2021
All news about AMAZON.COM, INC.
01:57pAMAZON COM : MacKenzie Scott dominates donations to racial equity
AQ
11:52aAMAZON COM : faces Teamsters union drive at nine Canadian sites
RE
09:00aAMAZON COM : HBO Max slashes prices in limited offer as streaming wars heat up
RE
08:13aAMAZON COM : Love Hemp Secures First Order from Amazon
MT
06:01aAMAZON CAREER DAY 2021 : More Than 1 Million People Apply for Jobs at Amazon
BU
04:51aBanks beware, outsiders are cracking the code for finance
RE
04:33aAmazon.com Hiring Event Draws 1 Million Applicants
DJ
09/16AMAZON COM : S&P ends modestly lower as rising Treasury yields offset robust ret..
RE
09/16AMAZON COM : donates over 550,000 supplies to areas hit by Hurricane Ida
PU
09/16S&P ends slightly lower as rising Treasury yields offset robust retail data
RE
More news
Analyst Recommendations on AMAZON.COM, INC.
More recommendations
Financials (USD)
Sales 2021 476 B - -
Net income 2021 27 103 M - -
Net cash 2021 57 789 M - -
P/E ratio 2021 66,3x
Yield 2021 -
Capitalization 1 767 B 1 767 B -
EV / Sales 2021 3,59x
EV / Sales 2022 2,97x
Nbr of Employees 1 298 000
Free-Float 82,5%
Chart AMAZON.COM, INC.
Duration : Period :
Amazon.com, Inc. Technical Analysis Chart | AMZN | US0231351067 | MarketScreener
Technical analysis trends AMAZON.COM, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 47
Last Close Price 3 488,24 $
Average target price 4 184,10 $
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
Andrew R. Jassy President, Chief Executive Officer & Director
Brian T. Olsavsky Chief Financial Officer & Senior Vice President
Jeffrey P. Bezos Executive Chairman
Patricia Q. Stonesifer Independent Director
Thomas O. Ryder Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AMAZON.COM, INC.6.72%1 766 586
JD.COM, INC.-12.21%119 780
WAYFAIR INC.23.05%28 871
ETSY, INC.25.99%28 372
ALLEGRO.EU SA-25.95%16 516
MOMO.COM INC.319.62%13 769